Imunon Overview
- Year Founded
-
1982
- Status
-
Public
- Employees
-
20
- Stock Symbol
-
IMNN
- Investments
-
1
- Share Price
-
$0.53
- (As of Friday Closing)
Imunon General Information
Description
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Contact Information
Website
www.imunon.comCorporate Office
- 997 Lenox Drive
- Suite 100
- Lawrenceville, NJ 08648
- United States
Corporate Office
- 997 Lenox Drive
- Suite 100
- Lawrenceville, NJ 08648
- United States
Imunon Timeline
Imunon Stock Performance
As of 20-Nov-2026, Imunon’s stock price is $0.53. Its current market cap is $3.47M with 6.49M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.53 | $0.56 | $0.49 - $4.35 | $3.47M | 6.49M | 150K | -$3.31 |
Imunon Financials Summary
As of 30-Sep-2026, Imunon has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 8,220 | 7,549 | 4,730 | (11,249) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (14,363) | (13,796) | (17,902) | (20,604) |
| Net Income | (15,036) | (14,495) | (18,620) | (19,515) |
| Total Assets | 12,009 | 12,288 | 9,717 | 21,918 |
| Total Debt | 6,937 | 1,009 | 1,139 | 1,625 |
Imunon Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Imunon Comparisons
Industry
Financing
Details
Imunon Competitors (46)
One of Imunon’s 46 competitors is Renova Therapeutics, a Venture Capital-Backed company based in Carlsbad, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Protalix Biotherapeutics | Formerly VC-backed | Karmiel, Israel | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Mustang Bio | Formerly VC-backed | Waltham, MA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE |
Imunon Patents
Imunon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4658324-A1 | Process for producing dna formulations with lipopolymer delivery systems | Pending | 31-Jan-2023 | ||
| US-20260216375-A1 | Process for producing dna formulations with lipopolymer delivery systems | Pending | 31-Jan-2023 | ||
| WO-2024163503-A1 | Process for producing dna formulations with lipopolymer delivery systems | Inactive | 31-Jan-2023 | ||
| EP-4587459-A1 | Il-12 gene therapy and immune checkpoint inhibitor combination for treating cancer | Pending | 13-Sep-2022 | ||
| EP-4587459-A4 | Il-12 gene therapy and immune checkpoint inhibitor combination for treating cancer | Pending | 13-Sep-2022 | A61K39/00 |
Imunon Signals
Imunon Acquisitions (1)
Imunon’s most recent deal was a Merger/Acquisition with EGEN (Pharmaceuticals) for . The deal was made on 20-Jun-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| EGEN (Pharmaceuticals) | 20-Jun-2014 | Merger/Acquisition | Drug Discovery |
Imunon ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.72 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Imunon FAQs
-
When was Imunon founded?
Imunon was founded in 1982.
-
Where is Imunon headquartered?
Imunon is headquartered in Lawrenceville, NJ.
-
What is the size of Imunon?
Imunon has 20 total employees.
-
What industry is Imunon in?
Imunon’s primary industry is Drug Discovery.
-
Is Imunon a private or public company?
Imunon is a Public company.
-
What is Imunon’s stock symbol?
The ticker symbol for Imunon is IMNN.
-
What is the current stock price of Imunon?
As of 20-Nov-2026 the stock price of Imunon is $0.53.
-
What is the current market cap of Imunon?
The current market capitalization of Imunon is $3.47M.
-
Who are Imunon’s competitors?
Renova Therapeutics, Protalix Biotherapeutics, Astellas Pharma, Mustang Bio, and Ayala Pharmaceuticals are some of the 46 competitors of Imunon.
-
What is Imunon’s annual earnings per share (EPS)?
Imunon’s EPS for 12 months was -$3.31.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process